| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acting on misinformation to prevent patient harm
|
The Lancet Oncology,
|
|
|
21 |
9 |
p. 1123
|
artikel
|
| 2 |
Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study
|
Liu, Chao
|
|
|
21 |
9 |
p. 1244-1252
|
artikel
|
| 3 |
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
|
Yang†, Xu
|
|
|
21 |
9 |
p. e412
|
artikel
|
| 4 |
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma – Authors' replys
|
Lee, Kyung-Hun
|
|
|
21 |
9 |
p. e413
|
artikel
|
| 5 |
Carboplatin plus etoposide or topotecan for small-cell lung cancer
|
Arrieta, Oscar
|
|
|
21 |
9 |
p. 1132-1134
|
artikel
|
| 6 |
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
|
Baize, Nathalie
|
|
|
21 |
9 |
p. 1224-1233
|
artikel
|
| 7 |
Chemoradiotherapy plus a SMAC mimetic for locally advanced squamous cell carcinoma of the head and neck
|
Voortman, Jens
|
|
|
21 |
9 |
p. 1126-1128
|
artikel
|
| 8 |
Correction to Lancet Oncol 2020; 21: 935–46
|
|
|
|
21 |
9 |
p. e418
|
artikel
|
| 9 |
Correction to Lancet Oncol 2020; 21: 1125–26
|
|
|
|
21 |
9 |
p. e418
|
artikel
|
| 10 |
Correction to Lancet Oncol 2020; 21: 1017–18
|
|
|
|
21 |
9 |
p. e418
|
artikel
|
| 11 |
Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
|
Subbiah, Vivek
|
|
|
21 |
9 |
p. 1234-1243
|
artikel
|
| 12 |
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
|
Sun, Xu-Shan
|
|
|
21 |
9 |
p. 1173-1187
|
artikel
|
| 13 |
Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines
|
Gupta, Sumit
|
|
|
21 |
9 |
p. e444-e451
|
artikel
|
| 14 |
Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy
|
Tran, Audrey A
|
|
|
21 |
9 |
p. 1134-1136
|
artikel
|
| 15 |
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
|
Nowak, Anna K
|
|
|
21 |
9 |
p. 1213-1223
|
artikel
|
| 16 |
Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial
|
Duffy, Stephen W
|
|
|
21 |
9 |
p. 1165-1172
|
artikel
|
| 17 |
Final results of the UK Age trial on breast cancer screening age
|
Miller, Anthony B
|
|
|
21 |
9 |
p. 1125-1126
|
artikel
|
| 18 |
Gender balance at oncology conferences in China
|
Biskup, Ewelina
|
|
|
21 |
9 |
p. 1138-1140
|
artikel
|
| 19 |
Head and neck surgery recommendations during the COVID-19 pandemic
|
Galloway, Thomas J
|
|
|
21 |
9 |
p. e416
|
artikel
|
| 20 |
Head and neck surgery recommendations during the COVID-19 pandemic – Author's reply
|
Mehanna, Hisham
|
|
|
21 |
9 |
p. e417
|
artikel
|
| 21 |
Maintenance after allogeneic HSCT in acute myeloid leukaemia
|
Mohty, Mohamad
|
|
|
21 |
9 |
p. 1130-1132
|
artikel
|
| 22 |
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
|
Bodei, Lisa
|
|
|
21 |
9 |
p. e431-e443
|
artikel
|
| 23 |
Multiple brown papules at the site of mastectomy for breast cancer
|
Bourlond, Florence
|
|
|
21 |
9 |
p. e460
|
artikel
|
| 24 |
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
|
Domchek, Susan M
|
|
|
21 |
9 |
p. 1155-1164
|
artikel
|
| 25 |
Open notes in cancer care: coming soon to patients
|
Blease, Charlotte
|
|
|
21 |
9 |
p. 1136-1138
|
artikel
|
| 26 |
Patients with cancer hit hard by deadly explosions in Beirut
|
Gourd, Elizabeth
|
|
|
21 |
9 |
p. 1143
|
artikel
|
| 27 |
Potential new method for rapid diagnosis of radiation sickness
|
Gourd, Elizabeth
|
|
|
21 |
9 |
p. 1142
|
artikel
|
| 28 |
PROPHYLOCHIP: no benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases
|
Moran, Brendan J
|
|
|
21 |
9 |
p. 1124-1125
|
artikel
|
| 29 |
Ripretinib for advanced gastrointestinal stromal tumours
|
Dekker, Tim J A
|
|
|
21 |
9 |
p. e414
|
artikel
|
| 30 |
Ripretinib for advanced gastrointestinal stromal tumours – Authors' reply
|
Blay, Jean-Yves
|
|
|
21 |
9 |
p. e415
|
artikel
|
| 31 |
Risk factors for in-hospital mortality in patients with cancer and COVID-19
|
Zhang, Guosen
|
|
|
21 |
9 |
p. e407
|
artikel
|
| 32 |
Risk factors for in-hospital mortality in patients with cancer and COVID-19
|
Guo, Kaibo
|
|
|
21 |
9 |
p. e406
|
artikel
|
| 33 |
Risk factors for in-hospital mortality in patients with cancer and COVID-19 – Authors' reply
|
Yang, Kunyu
|
|
|
21 |
9 |
p. e408
|
artikel
|
| 34 |
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study
|
Goéré, Diane
|
|
|
21 |
9 |
p. 1147-1154
|
artikel
|
| 35 |
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
|
Xuan, Li
|
|
|
21 |
9 |
p. 1201-1212
|
artikel
|
| 36 |
Terminal agitation and delirium in patients with cancer
|
Schlögl, Mathias
|
|
|
21 |
9 |
p. e410
|
artikel
|
| 37 |
Terminal agitation and delirium in patients with cancer
|
Kako, Jun
|
|
|
21 |
9 |
p. e409
|
artikel
|
| 38 |
Terminal agitation and delirium in patients with cancer – Authors' reply
|
Hui, David
|
|
|
21 |
9 |
p. e411
|
artikel
|
| 39 |
The Lancet Oncology at 20—two decades of influencing the oncology landscape
|
Collingridge, David
|
|
|
21 |
9 |
p. 1140-1141
|
artikel
|
| 40 |
The science of hope
|
Corn, Benjamin W
|
|
|
21 |
9 |
p. e452-e459
|
artikel
|
| 41 |
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
|
Ochoa de Olza, María
|
|
|
21 |
9 |
p. e419-e430
|
artikel
|
| 42 |
Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia
|
Seymour, John F
|
|
|
21 |
9 |
p. 1128-1130
|
artikel
|
| 43 |
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
|
Al-Sawaf, Othman
|
|
|
21 |
9 |
p. 1188-1200
|
artikel
|
| 44 |
Vision 2020: looking back and thinking forward on The Lancet Oncology Commissions
|
Gospodarowicz, Mary K
|
|
|
21 |
9 |
p. 1144-1146
|
artikel
|
| 45 |
20 years of The Lancet Oncology: how scientific should oncology be?
|
Lee, John
|
|
|
21 |
9 |
p. e461
|
artikel
|
Tijdschrift beschrijving